Pfizer. has been granted a patent for humanized anti-CD47 antibodies, including masked variants, aimed at treating CD47-expressing cancers. The patent details methods for administering these antibodies to inhibit the proliferation of cancer cells associated with CD47 expression. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of July 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-cd47 antibodies for treating cd47-expressing cancers
The granted patent US12071480B2 outlines a method for treating cancers that express CD47, a protein often associated with immune evasion in tumors. The method involves administering a therapeutically effective amount of an anti-CD47 antibody or its antigen-binding fragment, which is characterized by specific variable regions and high sequence identity to designated sequences. The claims detail the identification of subjects with CD47-expressing cancers, which can include both hematological and solid tumors, through methods such as isolating cancer tissue and detecting CD47 or assessing macrophage infiltration levels. The patent specifies various types of cancers that can be targeted, including non-Hodgkin lymphoma, multiple myeloma, and various solid tumors like lung and breast cancer.
Additionally, the patent describes potential combinations of the anti-CD47 antibody with other therapeutic agents, such as immune checkpoint inhibitors and agonistic anti-CD40 antibodies, to enhance treatment efficacy. The claims also cover the use of antibody-drug conjugates (ADCs) that link the anti-CD47 antibody to cytotoxic agents, thereby facilitating targeted delivery of treatment to cancer cells. The detailed specifications regarding the antibody's structure and the methods for identifying suitable patients underscore the patent's focus on precision medicine in oncology, aiming to improve therapeutic outcomes for patients with CD47-expressing cancers.
To know more about GlobalData’s detailed insights on Pfizer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
